Display options
Cite
Dimitrova M, Petrova G, Tachkov K, et al. Economic consequences of the vaccination against hepatitis A in the Bulgarian healthcare setting. Biotechnol Biotechnol Equip. 2014;28(2):366-371doi: 10.1080/13102818.2014.909654.
Dimitrova, M., Petrova, G., Tachkov, K., Bozhkova, M. K., Kamusheva, M., & Mitov, K. (2014). Economic consequences of the vaccination against hepatitis A in the Bulgarian healthcare setting. Biotechnology, biotechnological equipment, 28(2), 366-371. https://doi.org/10.1080/13102818.2014.909654
Dimitrova, Maria, et al. "Economic consequences of the vaccination against hepatitis A in the Bulgarian healthcare setting." Biotechnology, biotechnological equipment vol. 28,2 (2014): 366-371. doi: https://doi.org/10.1080/13102818.2014.909654
Dimitrova M, Petrova G, Tachkov K, Bozhkova MK, Kamusheva M, Mitov K. Economic consequences of the vaccination against hepatitis A in the Bulgarian healthcare setting. Biotechnol Biotechnol Equip. 2014 Mar 04;28(2):366-371. doi: 10.1080/13102818.2014.909654. Epub 2014 Jul 10. PMID: 26019522; PMCID: PMC4433896.
Copy Download .nbib Format: NLM
Share it on

Biotechnol Biotechnol Equip. 2014 Mar 04;28(2):366-371. doi: 10.1080/13102818.2014.909654. Epub 2014 Jul 10.

Economic consequences of the vaccination against hepatitis A in the Bulgarian healthcare setting.

Biotechnology, biotechnological equipment

Maria Dimitrova, Guenka Petrova, Konstantin Tachkov, Maria Krasteva Bozhkova, Maria Kamusheva, Konstantin Mitov

Affiliations

  1. Organization and Economy of Pharmacy, Faculty of Pharmacy, Medical University of Sofia , Sofia , Bulgaria.
  2. Medicine College, Medical University of Plovdiv , Plovdiv , Bulgaria.

PMID: 26019522 PMCID: PMC4433896 DOI: 10.1080/13102818.2014.909654

Abstract

The purpose of the present analysis is to calculate and compare the costs and results of the implication of the inactivated vaccine against hepatitis A virus (HAV) in the Bulgarian healthcare setting in the period of 2002-2012. A combined pharmacoeconomic and epidemiological study was performed on the basis of the prevalence of hepatitis A infection in this 10-year period. The investments in the vaccination were considered as costs and the avoided costs in the case of vaccination of all one-year old children in the population - as benefits. The results show that the vaccination of one-year-old children would be cost effective to the healthcare system in the years with an epidemiologic outbreak, as in these years the total cost of treatment of patients with hepatitis A infection exceeds the cost for vaccination of the whole one-year-old cohort. The critical threshold is 4600 infected patients per year that equalize the benefits to costs. The inclusion of HAV vaccine in the National Immunization Calendar would be cost effective for the healthcare system when the vaccination is performed in certain risk groups and could help to decrease the circulation of the virus in the general population.

Keywords: HAV vaccine; cost of vaccination; cost–benefit analysis; prevalence

References

  1. Vaccine. 1999 Apr 9;17(15-16):1919-25 - PubMed
  2. Vaccine. 1999 Nov 12;18(7-8):656-64 - PubMed
  3. Am J Gastroenterol. 2000 Jan;95(1):223-6 - PubMed
  4. Vaccine. 2003 Jun 2;21(19-20):2250-7 - PubMed
  5. Vaccine. 1992;10 Suppl 1:S160-8 - PubMed
  6. Vaccine. 1992;10 Suppl 1:S93-6 - PubMed
  7. Vaccine. 2004 May 7;22(15-16):1862-7 - PubMed
  8. Vaccine. 2005 Jul 14;23(32):4110-9 - PubMed
  9. Pharmacoeconomics. 2008;26(1):17-32 - PubMed
  10. J Viral Hepat. 2008 Oct;15 Suppl 2:47-50 - PubMed
  11. Pharmacoeconomics. 2009;27(5):379-89 - PubMed
  12. Vaccine. 2012 Sep 14;30(42):6070-80 - PubMed
  13. Wkly Epidemiol Rec. 2012 Jul 13;87(28/29):261–76 - PubMed
  14. Bull World Health Organ. 1995;73(1):15-20 - PubMed
  15. CMAJ. 1995 Feb 1;152(3):343-8 - PubMed

Publication Types